Document Detail

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity.
MedLine Citation:
PMID:  11439290     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Peripheral infusions of glucagon-like peptide-1 (GLP-1) in humans have been shown to inhibit gastrointestinal motility and decrease hunger and energy intake. However, these investigations used supraphysiological doses. The objective of this study was to investigate the effects of a GLP-1 infusion in a physiological dose on appetite sensations, energy intake, gastric emptying, energy and substrate metabolism.
METHODS: Eighteen obese men participated in the placebo-controlled, randomized, single-blinded, cross-over study with infusion of GLP-1 or saline. Resting metabolic rate (RMR) and substrate oxidations were measured by ventilated hood before and after an energy-fixed breakfast. Gastric emptying was measured using paracetamol as a marker. Visual analogue scales were used to assess appetite sensations, thirst and comfort throughout the experiment and palatability of the test meals. Blood was sampled for analysis of hormones (GLP-1, GLP-2, glucose-dependent insulinotropic polypeptide (GIP), insulin, glucagon), and substrates (glucose, lactate, non-esterified fatty acids (NEFA), triacylglycerol (TAG)). Ad libitum energy intake at lunch was registered.
RESULTS: Following the breakfast, GLP-1 infusion suppressed ratings of hunger and prospective food consumption (P<0.05), whereas all other subjective ratings and ad libitum energy intake were unaffected. RMR, carbohydrate oxidation and gastric emptying rate were lower during the GLP-1 infusion compared with the saline infusion (P<0.001, P<0.05, P<0.0001, respectively). All plasma hormone and substrate profiles, except NEFA, were significantly reduced by GLP-1 (P<0.0001).
CONCLUSION: It is concluded that GLP-1 in physiological concentrations powerfully reduces the rate of entry of nutrients into the circulation by a reduction of gastric emptying rate in obese subjects. The effect of GLP-1 on appetite and food intake may be beneficial in weight reduction.
A Flint; A Raben; A K Ersbøll; J J Holst; A Astrup
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity     Volume:  25     ISSN:  -     ISO Abbreviation:  Int. J. Obes. Relat. Metab. Disord.     Publication Date:  2001 Jun 
Date Detail:
Created Date:  2001-07-05     Completed Date:  2001-12-13     Revised Date:  2014-06-03    
Medline Journal Info:
Nlm Unique ID:  9313169     Medline TA:  Int J Obes Relat Metab Disord     Country:  England    
Other Details:
Languages:  eng     Pagination:  781-92     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Appetite / drug effects*
Basal Metabolism
Body Mass Index
Energy Metabolism / drug effects*
Gastric Emptying / drug effects*
Glucagon / blood,  pharmacology*
Glucagon-Like Peptide 1
Obesity / drug therapy*,  physiopathology
Peptide Fragments / blood,  pharmacology*
Protein Precursors / blood,  pharmacology*
Reg. No./Substance:
0/Peptide Fragments; 0/Protein Precursors; 89750-14-1/Glucagon-Like Peptide 1; 9007-92-5/Glucagon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  G-protein beta3 subunit gene splice variant in obesity and overweight.
Next Document:  A disparity between conventional lipid and insulin resistance markers at body mass index levels grea...